Search

Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.

… Tuesday, September 20, 2016 Gerstner Sloan Kettering graduate James Mahaffey works in a lab at the Perlmutter Cancer Center at NYU School of Medicine exploring the RAS gene, which is mutated in nearly a third of cancers but has resisted targeting with drugs. James Mahaffey studies RAS, a gene that is

Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.

… Wednesday, October 1, 2014 VIDEO | 04:30 Virtual Tour of Memorial Sloan Kettering Cancer Center Westchester Take a virtual tour of our suburban outpatient location and hear from our doctors on the benefits of receiving care at MSK Westchester. Video Details Memorial Sloan Kettering’s suburban presence

Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.

… Friday, September 3, 2021 Right now, in your body, lurk thousands of cells with DNA mistakes that could cause cancer. Yet only in rare instances do these DNA mistakes, called genetic mutations, lead to a full-blown cancer. Why? The standard explanation is that it takes a certain number of genetic “hits

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.

… Tuesday, December 26, 2023 Physicians and researchers at  MSK Kids , Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic

In 1971, Richard Nixon launched a “war on cancer.” It’s still raging.

… Wednesday, January 1, 2020 In 2016, when Vice President Joseph Biden announced the “Cancer Moonshot” initiative , many in the scientific world felt a twinge of déjà vu. This wasn’t the first time that officials in the US government had set their sights on an ambitious plan to conquer cancer. In fact,

Learn how MSK researchers are deploying mRNA vaccines against pancreatic cancer.

… Sunday, April 19, 2026 An experimental, individualized therapeutic cancer vaccine that uses messenger RNA (mRNA) to treat pancreatic cancer continues to show potential in a small patient group. Follow-up results from a phase 1 clinical trial show that nearly 90% of people whose immune systems responded

Nick Kroll, Brett Goldstein, Zarna Garg, Hasan Minhaj, Bridget Everett, and special guests took the stage for a one-night-only event, raising $2.5 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life

… Monday, April 20, 2026 Comedy vs Cancer , the official comedy benefit show for blood cancer research at Memorial Sloan Kettering Cancer Center (MSK), returned to Jazz at Lincoln Center’s Frederick P. Rose Hall. The sold-out, one-night-only event raised more than $2.5 million to support lifesaving blood

Learn how a new drug shows great promise for treating pancreatic by targeting the KRAS mutation, which fuels 90% of the disease.

… Tuesday, April 21, 2026 A drug given “breakthrough designation” by the U.S. Food & Drug Administration (FDA) may offer the best new option in many years for people facing pancreatic cancer , one of the most aggressive types of cancer.  Daraxonrasib targets mutations in the RAS gene, which helps control

MSK experts presented findings from their latest foundational and translational oncology research at the 2026 AACR Annual Meeting. Highlights included treatment of early-stage rectal cancer with protein inhibitors targeting HER2, recent data from the personalized RNA vaccine trial for pancreatic cancer, and development of a framework to understand biomarkers and vulnerabilities during the early to late stages of transitions from lung cancer-enabling adenomas to neuroendocrine lineage plasticity.

… Tuesday, April 21, 2026 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational oncology research at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17 to 22 in San Diego. Highlights included treatment

MSK scientists are shedding new light on a tumor’s earliest moments — revealing how lung cells with cancer-causing mutations recruit accomplices from healthy surrounding tissue to pave the way for a tumor to develop.

… Wednesday, April 22, 2026 Scientists at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues are shedding new light on a tumor’s earliest moments — revealing how lung cells with cancer-causing mutations recruit accomplices from healthy surrounding tissue to pave the way for a tumor to develop